Trial Profile
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
Status:
Suspended
Phase of Trial:
Phase III
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs Inotuzumab ozogamicin (Primary) ; Allopurinol; Cyclophosphamide; Cytarabine; Cytarabine; Cytarabine; Daunorubicin; Dexamethasone; Dexamethasone; Doxorubicin; Mercaptopurine; Methotrexate; Methotrexate; Methotrexate; Pegaspargase; Rituximab; Tioguanine; Vincristine
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 03 Apr 2023 Planned primary completion date changed from 1 Mar 2023 to 1 Mar 2024.
- 24 May 2022 Status changed from recruiting to suspended (Due to Unacceptable Toxicity).
- 19 Jul 2018 Status changed from suspended to recruiting.